All In Biotech

Drug Trial Radar · NCT02227849

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to GLP-1 Analogue in Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

71

Actual

Start

Aug 2014

Primary completion

Mar 2016

Study completion Mar 2016

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Aug 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with GLP-1 analogue in patients with type 2 Diabetes for 52 weeks.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Canagliflozin (TA-7284)Drug

    The patients will receive Canagliflozin orally for 52 weeks

  • GLP-1 analogueDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events)Time frame: 52 Weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Reserch site

    Chūbu, Japan

  • Reserch site

    Hokkaido, Japan

  • Reserch site

    Kanto, Japan

  • Reserch site

    Kinki, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.